These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36115673)

  • 1. Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma.
    Zhang B; Yue J; Shi X; Cui K; Li L; Zhang C; Sun P; Zhong J; Li Z; Zhao L
    BMJ Open; 2022 Sep; 12(9):e060955. PubMed ID: 36115673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial.
    Li Z; Liu J; Zhang B; Yue J; Shi X; Cui K; Liu Z; Chang Z; Sun Z; Li M; Yang Y; Ma Z; Li L; Zhang C; Sun P; Zhong J; Zhao L
    Nat Commun; 2024 Apr; 15(1):3260. PubMed ID: 38627377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of SBRT combined with sintilimab and IBI305 in patients with advanced HCC and previously failed immunotherapy: study protocol of a phase 2 clinical trial.
    Zhang J; Yang Y; Wu Z; Zhang S; Lin Z; Liu H; Hu J; Zhang T; Tang J; Xue J
    BMJ Open; 2024 Jun; 14(6):e077903. PubMed ID: 38858156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
    Marron TU; Fiel MI; Hamon P; Fiaschi N; Kim E; Ward SC; Zhao Z; Kim J; Kennedy P; Gunasekaran G; Tabrizian P; Doroshow D; Legg M; Hammad A; Magen A; Kamphorst AO; Shareef M; Gupta NT; Deering R; Wang W; Wang F; Thanigaimani P; Mani J; Troncoso L; Tabachnikova A; Chang C; Akturk G; Buckup M; Hamel S; Ioannou G; Hennequin C; Jamal H; Brown H; Bonaccorso A; Labow D; Sarpel U; Rosenbloom T; Sung MW; Kou B; Li S; Jankovic V; James N; Hamon SC; Cheung HK; Sims JS; Miller E; Bhardwaj N; Thurston G; Lowy I; Gnjatic S; Taouli B; Schwartz ME; Merad M
    Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):219-229. PubMed ID: 35065058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer.
    Li J; Bai Y; Chen Z; Ying J; Guo Y; Fang W; Zhang F; Xiong J; Zhang T; Meng Z; Zhang J; Ren Z; Hao C; Chen Y; Lin X; Pan H; Zhou F; Li X; Yu F; Zhang J; Zhang Z; Qin S
    Cancer Immunol Immunother; 2024 Sep; 73(11):219. PubMed ID: 39235596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
    Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial).
    Pang K; Yang Y; Tian D; Zeng N; Cao S; Ling S; Gao J; Zhao P; Wang H; Kong Y; Zhang J; Chen G; Deng W; Bai Z; Jin L; Wu G; Zhu D; Wang Y; Zhou J; Wu B; Lin G; Xiao Y; Gao Z; Ye Y; Wang X; Li A; Han J; Yao H; Yang Y; Zhang Z
    BMJ Open; 2023 Sep; 13(9):e069499. PubMed ID: 37699634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).
    Yang Z; Zhang X; Zhang J; Gao J; Bai Z; Deng W; Chen G; An Y; Liu Y; Wei Q; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
    BMC Cancer; 2022 Apr; 22(1):462. PubMed ID: 35477432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial.
    Ogasawara S; Koroki K; Makishima H; Wakatsuki M; Takahashi A; Yumita S; Nakagawa M; Ishino T; Ogawa K; Fujiwara K; Iwanaga T; Sakuma T; Fujita N; Kojima R; Kanzaki H; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Ozawa Y; Kawasaki Y; Kurokawa T; Hanaoka H; Tsuji H; Kato N
    BMJ Open; 2022 Apr; 12(4):e059779. PubMed ID: 35396315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
    Altorki NK; McGraw TE; Borczuk AC; Saxena A; Port JL; Stiles BM; Lee BE; Sanfilippo NJ; Scheff RJ; Pua BB; Gruden JF; Christos PJ; Spinelli C; Gakuria J; Uppal M; Binder B; Elemento O; Ballman KV; Formenti SC
    Lancet Oncol; 2021 Jun; 22(6):824-835. PubMed ID: 34015311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer.
    Lu C; Zhu Y; Kong W; Yang J; Zhu L; Wang L; Tang M; Chen J; Li Q; He J; Li A; Qiu X; Gu Q; Chen D; Meng F; Liu B; Qiu Y; Du J
    Front Oncol; 2022; 12():879661. PubMed ID: 36059628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
    Pinato DJ; Cortellini A; Sukumaran A; Cole T; Pai M; Habib N; Spalding D; Sodergren MH; Martinez M; Dhillon T; Tait P; Thomas R; Ward C; Kocher H; Yip V; Slater S; Sharma R
    BMC Cancer; 2021 Mar; 21(1):301. PubMed ID: 33757459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
    He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
    Front Immunol; 2022; 13():853922. PubMed ID: 35720312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment of HCC with SBRT and immune checkpoint inhibition.
    Podesta C; Kayani M; Goody R; Samson A
    Crit Rev Oncol Hematol; 2023 Dec; 192():104191. PubMed ID: 37865277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
    Xia Y; Tang W; Qian X; Li X; Cheng F; Wang K; Zhang F; Zhang C; Li D; Song J; Zhang H; Zhao J; Yao A; Wu X; Wu C; Ji G; Liu X; Zhu F; Qin L; Xiao X; Deng Z; Kong X; Li S; Yu Y; Xi W; Deng W; Qi C; Liu H; Pu L; Wang P; Wang X
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial.
    Shi C; Li Y; Geng L; Shen W; Sui C; Dai B; Lu J; Pan M; Yang J
    Eur J Cancer; 2022 May; 166():176-184. PubMed ID: 35303509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant systemic therapy for hepatocellular carcinoma.
    Chick RC; Ruff SM; Pawlik TM
    Front Immunol; 2024; 15():1355812. PubMed ID: 38495884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.